Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged

Cancer Cell

Volumn 26, Issue 5, 2014, Pages 603-604

  Chapman, Paul B ^a,b   Solit, David B ^a,b   Rosen, Neal ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF PROTEIN; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE;

CANCER SURVIVAL; CELL DAMAGE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERKERATOSIS; MELANOMA; MONOTHERAPY; PROGRESSION FREE SURVIVAL; RASH; RETINOPATHY; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN HYPERTROPHY; TREATMENT RESPONSE; TUMOR CELL; WILD TYPE; ANTAGONISTS AND INHIBITORS; FEEDBACK SYSTEM; GENETICS; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEEDBACK, PHYSIOLOGICAL; HUMANS; MAP KINASE KINASE KINASES; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84912065268     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.10.017     Document Type: Short Survey

References (11)

1. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., et al. Nature 2010, 467:596-599.
2. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
3. Das Thakur M., Salangsang F., Landman A.S., Sellers W.R., Pryer N.K., Levesque M.P., Dummer R., McMahon M., Stuart D.D. Nature 2013, 494:251-255.
4. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., et al. N.Engl. J. Med. 2012, 367:107-114. METRIC Study Group.
5. Hauschild A., Grob J.-J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., et al. Lancet 2012, 380:358-365.
6. Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., et al. N.Engl. J. Med. 2014, Published online September 29, 2014. 10.1056/NEJMoa1408868.
7. Lito P., Pratilas C.A., Joseph E.W., Tadi M., Halilovic E., Zubrowski M., Huang A., Wong W.L., Callahan M.K., Merghoub T., et al. Cancer Cell 2012, 22:668-682.
8. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., et al. N.Engl. J. Med. 2014, Published online September 29, 2014. 10.1056/NEJMoa1406037.
9. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., et al. Nature 2011, 480:387-390.
10. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. Nature 2010, 464:427-430.
11. Wagle N., Van Allen E.M., Treacy D.J., Frederick D.T., Cooper Z.A., Taylor-Weiner A., Rosenberg M., Goetz E.M., Sullivan R.J., Farlow D.N., et al. Cancer Discov 2014, 4:61-68.